Wednesday, January 19, 2022 8:56:42 AM
Quote:
The LOI is the ROADMAP to the Definitive Agreement. The LOI was probably negotiated over a period of several weeks and was probably in negotiations when RGBP provided a Scope of Work order to Biotech Research Group directing Biotech Research Group to perform an independent assessment of work conducted to date on behalf of the Company by the Company’s Contract Research Organization in order to assist the Company in determining what would be the most efficient actions to undertake in order to commercialize the Company’s NR2F6 intellectual property as well as assist the Company with regulatory strategy with regard to the Company’s NR2F6 intellectual property .
Done some research in regard to the SCOPE OF WORK, this was not a value DETERMINATION report. This was to determine where RGBP WAS IN THE TESTING STAGE OF SCIENTIFIC PROCEDURES. Such evaluation can determine if they missed a procedure step and if any steps need to be repeated.
This is significant that KOOS had decided at this time to have all lab work verified, IMHO from my reading on the SOW (scope of work) ORDER evaluation process.
So to move to this process says Koos and his lab work procedures says they think there close. NOW IS NOT THE TIME TO SELL....HOLD
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM